ArticleMethods in molecular biology (Clifton, N.J.)2025
Optogenetic Engineered Living Materials.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered living materials (ELM) is a new frontier in materials research that uses living microorganisms to augment nonliving materials with lifelike capabilities, such as responding to external stimuli. This is achieved by genetically programming the microorganisms in an ELM with stimulus-sensing modules. A popular stimulus to remotely control various ELM functions is light, which has been realized thanks to optogenetics. This chapter describes methods to create a simple ELM capable of sensing light and responding to it by producing and releasing a drug. The material component of the ELM will be a Pluronic F127-based hydrogel and the living component will be optogenetically engineered bacteria. Such ELMs are being developed to create smart therapeutic solutions for challenging chronic diseases and variations in the design to improve performance and safety will be mentioned.
Indexed as
Identifiers
39724347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.